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Longitudinal assessment of metal concentrations and copper isotope ratios in 
the G93A SOD1 mouse model of amyotrophic lateral sclerosis 
Abstract 
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease, which involves progressive motor neuron 
degeneration in the central nervous system (CNS). The G93A SOD1 mouse model simulates one of the 
most common causes of familial ALS through the overexpression of a mutated form of the human gene 
encoding copper/zinc superoxide dismutase (SOD1). Transition metals, particularly Cu and Zn, have been 
shown to behave abnormally in the disease context and have been hypothesized to contribute to and 
potentially trigger the disease. In this study, concentrations of Cu, Zn and Fe, as well as Cu isotope ratios 
were assessed in keystone tissues of ALS, including the brain, spinal cord, muscle and whole blood, from 
transgenic mutant SOD1G93A mice and non-transgenic controls. While no consistent Cu isotope signal 
was found to be related to the disease state, concentrations of Cu, Zn and Fe were significantly elevated 
in muscle tissue of the transgenic mice, even at pre-symptomatic time points. In brain and muscle tissue, 
in both animal groups, a time-dependent Cu isotope signal was observed. We hypothesize that the early 
and significant elevation in metal concentration in muscle tissue from SOD1 transgenic mice could 
facilitate the development of ALS, without affecting the overall signal from well-buffered CNS tissues. 
Ageing may be recorded isotopically as a shift from a neonatal Cu pool as inherited from the mother, 
through dietary Cu and recycling processes. 
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Amyotrophic lateral sclerosis (ALS) is a motor neuron disease, which involves 
progressive motor neuron degeneration in the central nervous system (CNS). The 
G93A SOD1 mouse model simulates one of the most common causes of familial ALS 
through the overexpression of a mutated form of the human gene encoding 
copper/zinc superoxide dismutase (SOD1). Transition metals, particularly Cu and Zn, 
have been shown to behave abnormally in the disease context and have been 
hypothesized to contribute to and potentially trigger the disease. In this study, 
concentrations of Cu, Zn and Fe, as well as Cu isotope ratios were assessed in 
keystone tissues of ALS, including the brain, spinal cord, muscle and whole blood, 
from transgenic mutant SOD1
G93A
 mice and non-transgenic controls. While no 
consistent Cu isotope signal was found to be related to the disease state, 
concentrations of Cu, Zn and Fe were significantly elevated in muscle tissue of the 
transgenic mice, even at pre-symptomatic time points. In brain and muscle tissue, in 
both animal groups, a time-dependent Cu isotope signal was observed. We 
hypothesize that the early and significant elevation in metal concentration in muscle 
tissue from SOD1 transgenic mice could facilitate the development of ALS, without 
affecting the overall signal from well-buffered CNS tissues. Ageing may be recorded 
isotopically as a shift from a neonatal Cu pool as inherited from the mother, through 
dietary Cu and recycling processes. 
Significance to metallomics statement 
Copper has been hypothesized to play an important role in the development of 
amyotrophic lateral sclerosis, an adult onset neurodegenerative disease. Despite 
knowledge that Cu may contribute significantly, and possibly even trigger the disease 
phenotype in the central nervous system (CNS), the specific pathways remain 
obscure. In the present study, we hypothesize that the assessment of transition metal 
concentrations and Cu isotope ratios in the CNS, muscle and blood can facilitate a 
better understanding of the ALS aetiology.  
Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, resulting in 
the selective death of motor neurons (MNs).
1,2
 The degeneration of upper and lower 
motor neurons causes progressive muscle paralysis and spasticity, affecting mobility, 
speech, and respiration.
3
 Less than 20% of patients survive more than 5 years from 
diagnosis.
4
 Out of all ALS cases, 90-95% are described to be sporadic; the remaining 
5-10% familial.
2
 These familial cases are predominantly associated with Mendelian-
inherited mutations in the genes encoding for Cu,Zn superoxide dismutase (SOD1), 
TAR-DNA–binding protein 43 (TDP-43), fused in sarcoma/translocated in 




The first gene shown to be mutated in familial ALS encodes SOD1
5
 and since this 
discovery, over 150 pathogenic mutations in SOD1 have been identified in ALS 
patients.
6
 While these mutations account for about 20% of the familial cases of ALS
5
, 
the mechanisms behind the selective degeneration of MNs is still unclear; it has been 
proposed that a variety of pathophysiological processes play a role, including 
oxidative stress, glutamate-mediated excitotoxicity, protein aggregation and transition 
metal-induced toxicity.
7
 The toxicity induced by mutant SOD1 protein (mSOD1) is 
proposed to be a toxic gain-of-function rather than a loss of its dismutase activity,
8,9
 
as a result of increased propensity to destabilize, aggregate and misfold without 































































proper Zn and Cu coordination. To advance research into ALS, a transgenic mouse 
model was developed (mutant SOD1-G93A, SOD1
G93A
), in which human SOD1 
harboring the G93A mutation is overexpressed (20-24 fold higher expression than 
endogenous murine SOD1).
8
 This mSOD1 mouse model replicates many features of 
human ALS, including axonal and mitochondrial dysfunction, progressive 
neuromuscular dysfunction, gliosis and MN loss.
8,10,11
 While symptoms become 
obvious in this mouse model at ~100 days, pathological changes have been observed 
as early as 30 days of age.
12
 Results from experimental data suggest that the binding 




Transition metals such as Cu, Fe, and Zn, are essential trace elements that function as 
catalytic cofactors in metalloenzymes (e.g. SOD1 and catalase). At high 
concentrations, metals can be highly toxic.
16–18
 Therefore the concentrations of metals 
are maintained within a tight concentration range by proteins that mediate their 
uptake, distribution, storage and excretion.
19,20
 A growing body of evidence suggests 
the involvement of transition metals in the pathogenesis of neurodegenerative 
disorders, for example Cu and Fe in Parkinson’s,
19,21–23
 and Cu, Fe and Al in 
Alzheimer’s disease.
24–27
 However, the role of Cu and Zn homeostasis in the toxic 





Current research has not been able to attribute a single metal to be exclusively 
responsible for MN deterioration in ALS. In the cerebrospinal fluid (CSF) of patients 
with ALS, significantly elevated concentrations of Mn, Al, Cd, Co, Cu, Zn, Pb, V and 
U,
29
 as well as Mg, Fe, Cu and Zn
30
 have been observed, compared to healthy 
controls, suggesting an accumulation process. However, combinations or synergistic 
effects between metals may provide explanations to the neurodegeneration in ALS 




In the G93A mouse model of ALS, the diseased animals have been described to have 
significantly elevated concentrations of Cu in the spinal cord,
31–35
 and this 
concentration may increase over time with the progression of the disease.
36,37
 This 
increase in Cu concentration was hypothesized to be the result of a mSOD1-
dependent shift in intracellular Cu homeostasis toward Cu accumulation in the spinal 
cord during disease progression: Cu influx increases, Cu chaperones are up-regulated, 
and Cu efflux decreases.
37
 This proposed dysregulation within spinal MNs was 
proportionally associated with an age-dependent increase in Cu ion concentrations in 
the spinal cord.
37
 When testing the hypothesis that Cu concentrations increase in an 









), it was found that the amount of Cu bound to 
the SOD1 active site varied considerably between the mutants. Overall though Cu 
concentrations were, in every case, significantly increased compared to healthy 
controls.
32









), it was found that the SOD1 present 
in protein aggregates was metal deficient, irrespective of the ability of the mutant 
SOD1 isoforms to bind Cu.
38
 These results suggest a misbalance between the 
availability and demand for Cu in the cell. In the ventral horn of the spinal cord of the 
SOD
G85R
 mouse, Fe and Zn are increased in the gray matter, while there is no 
difference in Cu concentration between white and gray matter.
39
 While no significant 
difference between Cu concentrations in SOD1
G93A
 and non-transgenic littermates 































































(WT) brain samples were found,
31,36,37,40
 a subtle redistribution between the gray and 
white matter of the spinal cord was observed, with areas of higher Cu concentration 




In an ALS context, there is currently no consensus concerning Zn concentrations in 
the spinal cord and brain. When comparing spinal cord concentrations of Zn in tissue 




 and no 
difference
40
 in concentration have been reported. Tokuda et al. (2007)
36
 showed that 
Zn concentrations decreased over time in the spinal cord of diseased mice but 
remained constant in the brain. Contrastingly, Tokuda et al. (2013)
32
 found elevated 
Zn concentrations in diseased spinal cord tissue compared to transgenic WT animals, 
which overexpress wild type SOD1 rather than the mSOD1, while the concentrations 
of Mg, Ca, Al, Mn and Fe were not elevated. Other work indicated a disease-specific 











 In a mTDP-43
A315T
 mouse model of 
frontotemporal lobar degeneration and ALS, elevated concentrations of Zn, Cu and 
Mn were found in the spinal cord of diseased animals, while concentrations of these 




Iron metabolism has been previously studied in ALS patients, resulting in 
observations of elevated levels of serum ferritin
42–45
 and reduced levels of serum 
transferrin
43
, indicating high overall Fe concentrations in the body. Magnetic 
resonance imaging of ALS patients indicates abnormal Fe accumulation in the motor 
cortex,
46–48
 which could be responsible for inflammation and oxidative damage. 
Further findings of elevated Fe concentrations in human CSF
30
 and the presence of 
elevated Fe capable to promote free-radical generation
49
 contribute to the hypothesis 





It has been hypothesized that Cu isotopic ratios in blood and various organs should 
reflect the efficiency of overall body Cu metabolism,
51–55
 but only recently have tools 





are expected to distribute as a function of coordination and bond energy. Heavy 
isotopes are anticipated to be enriched in the strongest bonds, since the vibrational 
energy decreases at higher isotope mass.
56,57
 Hence, at the cellular level, it is likely 




Recent research has seen the application of medical isotope metallomics to a wide 
variety of medical problems.
56,60
 Important pilot studies were able to demonstrate the 
potential of medical isotope metallomics as a medical diagnostic tool: bone loss was 
traced via changes in Ca isotope ratios in blood and urine,
61,62
 cancer disease 
progression was traced via Cu and S isotopes in blood plasma,
59,63
 a correlation 
between liver cirrhosis severity and blood serum Cu isotope ratios was discovered
64
 
and breast cancer cells identified via Zn isotopes.
65,66
 The methodology was also 
applied to Parkinson’s disease, a neurodegenerative disease, where it was shown that 




The potential of medical isotope metallomics as a diagnostic tool has been reviewed 
for a variety of conditions.
67
 In this study it was tested whether there is a detectable 
longitudinal ALS-signal in metal (Cu, Zn, Fe) concentrations and Cu isotope ratios in 































































keystone tissues (brain, spinal cord, muscle tissue and whole blood) involved in the 
pathogenesis of ALS in the SOD1
G93A
 mouse model. These longitudinal results were 
collected to improve our understanding of the involvement of transition metals in the 
development of ALS and the potential for Cu isotopes to serve as a 
prognostic/diagnostic tool for the disease. 
 
Samples 
Transgenic mice in this study expressed the G93A mutant form of human SOD1 
(B6SJL-Tg(SOD1*G93A)1Gur/J)
8
 (Jackson Laboratory, ME, USA), from here on 
referred to as ‘SOD1
G93A
’. Healthy controls were non-transgenic littermates (WT). 
The mice were bred under specific conditions in accordance with Australian animal 
ethics laws at Australian Bioresources (Mossvale, NSW). The University of 
Wollongong animal ethics committee approved all experimental procedures (Ethics 
Number: AE14/28). All animals had free access to a uniform diet and water, and were 
held on a regulated 12 hours day-night light cycle. Mice were euthanized by CO2 
asphyxiation, immediately dissected to collect blood and various tissue samples, 
which were snap frozen in liquid nitrogen. All mice were female to avoid gender 
differences in the data. Mice were 30, 60, 90 or 120 days old (±2 days) to capture the 
characteristic disease progression typical for this mouse model.
68
 Samples of the 
uniform mouse food diet were randomly collected from various locations at the 
breeding facility (Australian Bioresources). Samples of DORM-2 dogfish muscle, 
certified reference material of the National Research Council Canada (CRM, NRCC), 




Mouse tissues, food and DORM-2 (~0.25 g) were weighed, and pre-digested in 
MARSXpress 20 mL PFA vessels in 2.5:1 mixture of 15 M Ultrapur® HNO3 (Merck) 
and Ultrapur® 30% H2O2 (Merck) for 30 minutes. These samples were further 
digested using a MARS6 (CEM Corporation, North Carolina, USA) microwave 
system at the University of Technology, Sydney. Temperature was ramped to 210 ºC 
over 15 min and then held constant for 150 min to ensure that all organic carbon was 
oxidized to CO2(g). For quality control purposes, one blank (acid only) and two 
DORM-2 aliquots were added to each digestion batch. Recovery of elements (Cu, Fe, 
Zn) from the DORM-2 certified reference material was used to control that the 
digestion of the biological samples was complete (Table 1). 
 




Element Certified Value 2SD Measured Value 2SD Recovery (%) 
Cu 2.34 0.16 2.4 0.3 103 
Fe 142 10 147 55 104 
Zn 25.6 2.3 28 8 109 
 
Elemental Concentrations  
Copper, Fe and Zn concentrations were determined using a Thermo Scientific iCAP-
Q quadrupole-inductively coupled plasma-mass spectrometer (Q-ICP-MS) at the 
Wollongong Isotope Geochronology Laboratory, University of Wollongong (WIGL, 
UOW). The concentrations were quantified using a multi-element standard external 
calibration curve; long-term instrument drift was corrected using a 50 ppb Ga solution 
as internal standard. Accuracy of the measurements were assessed through the 































































analysis of the DORM-2 CRM which yielded recoveries of 103% for Cu, 104% for Fe 
and 109% for Zn (Table 1). Reproducibility assessed through the analysis of DORM-
2 samples with every digestion batch was 12% for Cu, 30% for Zn and 55% for Fe 
(2RSTD). Total procedure blanks were assessed as <2 ng Cu, <4 ng Fe and <10 ng 
Zn. 
 
Copper Isotopic Measurement 
Copper was purified via ion exchange chromatography following the protocol 
described previously
69
 in a cleanroom (WIGL, UOW). The Cu eluates were 
evaporated to dryness and refluxed in 0.3 M HNO3. Stable Cu isotope analysis was 
performed via multi collector-inductively coupled plasma-mass spectrometer (MC-
ICP-MS), using a Neptune Plus (Thermo Scientific) at WIGL, UOW. Standard 
sample and skimmer cones, cyclonic spray chamber and PFA nebulizer with ~100 µL 
min
-1
 flow rate (Elemental Scientific, Omaha, USA) were used throughout. Routine 
instrument sensitivities of 20 V ppm
-1
 were achieved. The measurements were 
corrected for instrumental mass fractionation through a combination of internal 
correction with admixed Ni
70
 and applying Russell’s exponential law
71
. External 
normalization was achieved using a standard sample bracketing approach with the Cu 
isotopic reference material ERM-AE633 (European Commission, Geel, Belgium), as 
described previously elsewhere.
72,73
 Typical measurement accuracy of a synthetic 
standard solution (CuSRM-976, National Institute of Standards and Technology, 
Bethesda, MD, USA) was better than 0.01‰ (2SE; n = 197). Due to the lack of a 
certified biological isotopic reference material, the long-term measurement 
reproducibility and accuracy was tested on repeat measurements of food sample 
aliquots: δ
65
Cu = 0.84 ± 0.03‰ (2SE, n=6). Therefore the external error for the 
isotopic measurements is defined as 0.03‰ (2SE). The isotopic composition of Cu is 
expressed using the delta notation (δ
65
Cu, ‰) (Eqn. 1). Total procedure blanks were 
assessed to be <2 ng of Cu, therefore negligible compared to the usual 200-400 ng of 


















In order to assess the results from the measured data set, statistical analysis was 
performed. All statistical analyses were conducted using the statistical program R 
v3.3.1.
74
 Prior to analysis, outliers were removed using the median average deviation 
(3*mad). Any measurements outside 3*mad were considered to be measurement 
artifacts or the result of contamination. Data were analyzed through a linear 
regression model for each organ type with disease state and time used as independent 
variables and the measurements of Cu, Fe and Zn, as well as Cu isotope ratios, as 
dependent variables. Time was treated as a continuous variable. Likelihood ratio 
tests
75
 were used to determine which independent variables were significant. The 
assumptions of the linear regression model were checked, including normality tests 
for residuals. A significance level of α = 0.05 was used. 
 
Results  

































































In spinal cord tissues, Cu, Zn and Fe concentrations do not vary considerably between 
SOD1
G93A
 and WT samples (Table 2, 3 and Fig. 1A). Temporal behaviors of all three 
metals are similar in that they increase until 90 d and then decrease, with the 
exception of Zn in the SOD1
G93A
 tissue, where concentrations keep increasing until 
120 d (Fig. 1A-C). Zinc concentrations further show unexpectedly high values and 
large variability at 90 d.  
 
Brain 
Similarly to the spinal cord tissues, brain tissues also do not display a significant 
variation between SOD1
G93A
 and WT tissues for any of the assessed metals (Tables 2 
and 3). All three metals show similar trends with age, in both SOD1
G93A
 and WT, 
where concentrations increase until 60 or 90 d and then decrease. These trends appear 
to be more pronounced in Cu and Fe (Table 2 and Fig. 1D-F), but only reach 
statistical significance for Cu (p = 0.004). 
 
Muscle 
Different to the other tissues, concentrations in muscle tissue do vary significantly 
between SOD1
G93A
 and WT mice: Cu (p < 0.0005), Zn (p < 0.0005) and Fe (p = 
0.004) (Table 2, 3 and Fig. 1G-I). The difference between the concentrations in 
SOD1
G93A
 and WT mice appears to be a pre-symptomatic feature in Cu and trailing 
the development of symptoms (i.e. 60 d) in Zn and Fe (Fig. 1G-I).  The concentrations 
of all three metals increase until 90 d in the SOD1 tissue and then slightly decrease. In 
WT mice Cu, Zn and Fe concentrations are relatively constant over time (Fig. 1G-I), 
while the concentrations of Zn show a larger variability at 60 d.  
 
Whole Blood 
In whole blood, none of the analyzed metals vary significantly between SOD1
G93A
 
and WT mice (Table 2, Fig. 2). Iron concentrations demonstrated a significant trend 
over time (p = 0.05), where concentrations from both populations decrease between 
30-60 d and then increase until 120 d (Fig. 2C). 
 
Table 2 – Metal concentrations and Cu isotope ratios for spinal cord, brain and muscle 
tissues, and whole blood.
* 
 State n 30 d n 60d n 90d n 120 d  
Spinal cord          
Cu (µg g-1) 
SOD1G93A 6 9 ± 7 6 21 ± 12 5 19 ± 12 6 16 ± 14 
WT 7 12 ± 12 6 15 ± 10 6 18 ± 8 6 12 ± 11 
Zn (µg g-1) 
SOD1G93A 6 52 ± 28 6 83 ± 49 5 87 ± 60 6 89 ± 65 
WT 7 56 ± 43 6 53 ± 31 6 97 ± 59 5 45 ± 46 
Fe (µg g-1) 
SOD1G93A 6 56 ± 55 6 100 ± 80 5 104 ± 72 6 95 ± 69 
WT 7 90 ± 110 6 80 ± 54 6 109 ± 58 5 64 ± 21 
δ65Cu (‰) 
SOD1G93A 6 1.7 ± 0.8 6 1.4 ± 1.1 6 1.7 ± 1.2 6 1.6 ± 0.7 
WT 7 1.7 ± 0.7 6 2.1 ± 0.7 6 1.2 ± 0.6 6 1.5 ± 1.1 
          
Brain          
Cu (µg g-1) 
SOD1G93A 6 14 ± 2 6 27 ± 13 5 29 ± 14 6 25 ± 7 
WT 7 16 ± 6 6 28 ± 12 6 27 ± 19 6 23 ± 3 
Zn (µg g-1) 
SOD1G93A 6 87 ± 40 6 121 ± 50 5 94 ± 98 6 97 ± 38 
WT 7 76 ± 47 6 110 ± 45 6 108 ± 80 6 78 ± 18 
Fe (µg g-1) 
SOD1G93A 6 73 ± 18 6 122 ± 34 6 110 ± 120 6 94 ± 39 
WT 7 80 ± 25 6 128 ± 46 6 120 ± 84 6 102 ± 24 
δ65Cu (‰) SOD1G93A 6 1.8 ± 0.4 6 1.3 ± 0.8 6 1.5 ± 0.4 6 1.3 ± 0.4 































































WT 7 1.8 ± 0.8 6 1.6 ± 0.8 6 0.9 ± 2.2 6 1.4 ± 0.8 
          
Muscle          
Cu (µg g-1) 
SOD1G93A 6 7 ± 5 6 17 ± 8 6 24 ± 15 6 13 ± 5 
WT 6 5 ± 4 6 7 ± 5 5 6 ± 3 6 4 ± 1 
Zn (µg g-1) 
SOD1G93A 6 48 ± 20 6 97 ± 64 5 117 ± 63 6 95 ± 47 
WT 6 42 ± 19 6 68 ± 56 5 49 ± 24 6 37 ± 14 
Fe (µg g-1) 
SOD1G93A 6 47 ± 18 6 74 ± 26 5 146 ± 23 6 120 ± 96 
WT 6 50 ± 26 6 74 ± 42 5 65 ± 37 6 47 ± 6 
δ65Cu (‰) 
SOD1G93A 6 2.2 ± 1.8 6 1.0 ± 2.0 6 0.7 ± 0.9 6 0.5 ± 1.3 
WT 6 2.0 ± 1.6 6 1.7 ± 1.9 6 1.1 ± 2.2 6 0.7 ± 0.6 
          
Blood          
Cu (µg g-1) 
SOD1G93A 6 5 ± 3 7 3 ± 3 7 3 ± 4 8 4 ± 3 
WT 8 4 ± 2 8 3 ± 3 7 3 ± 4 8 3 ± 1 
Zn (µg g-1) 
SOD1G93A 7 25 ± 10 7 31 ± 21 7 35 ± 27 8 33 ± 19 
WT 9 23 ± 14 8 31 ± 27 7 34 ± 24 8 26 ± 7 
Fe (µg g-1) 
SOD1G93A 7 2100 ± 1800 7 1700 ± 1900 7 1600 ± 2500 8 2900 ± 1700 
WT 9 2200 ± 1700 8 1800 ± 2300 8 1800 ± 2700 8 3000 ± 500 
δ65Cu (‰) 
SOD1G93A 7 1.1 ± 0.7 8 0.7 ± 1.7 8 0.8 ± 1.2 8 1.3 ± 1.2 




) are presented for the diseased (SOD1
G93A
) and healthy, non-transgenic (WT) 
samples against time (in days; d). Errors shown are 2 standard deviations of the repeat measurements. 
 
Table 3 – Maximum and minimum metal concentrations and Cu isotope ratios for 
spinal cord, brain and muscle tissues, and whole blood. 
 SOD1G93A WT  
Spinal cord min max min max 
Cu (µg g-1) 4 24 4 24 
Zn (µg g-1) 27 122 20 142 
Fe (µg g-1) 35 183 46 195 
δ65Cu (‰) 0.8 2.4 0.8 2.5 
     
Brain     
Cu (µg g-1) 13 38 9 38 
Zn (µg g-1) 15 140 34 156 
Fe (µg g-1) 18 216 41 169 
δ65Cu (‰) 0.9 2.2 -1.3 2.2 
     
Muscle     
Cu (µg g-1) 4 39 3 11 
Zn (µg g-1) 15 140 34 156 
Fe (µg g-1) 37 205 38 102 
δ65Cu (‰) -0.2 3.9 0.4 3.3 
     
Blood     
Cu (µg g-1) 1 8 1 6 
Zn (µg g-1) 18 60 16 53 
Fe (µg g-1) 51 4008 48 4166 
δ65Cu (‰) -0.3 2.4 -0.1 2.2 
     
Feces     
Cu (µg g-1) 36 104 50 115 
Zn (µg g-1) 257 442 273 835 
Fe (µg g-1) 1011 2771 1099 1781 
δ65Cu (‰) 0.6 1.9 0.5 1.4 
 
Food and Feces 
Mouse food samples show Cu, Zn and Fe concentrations of 13.7 ± 0.5, 76 ± 5 and 340 
± 30 µg g-1, respectively (2SE, n = 6).  In feces, there is no significant difference in 
metal concentrations between SOD1
G93A
 and WT samples, and no trends over the age 
of the mice (Table 3 and 4).  
































































Copper isotope ratios 
Spinal cord 
In the spinal cord, Cu isotope ratios vary between 0.83 and 2.44‰ for SOD1G93A mice, 
and between 0.65 and 2.46‰ for WT mice (Fig. 3A, Table 3), with the difference 
only being significant at 60 d (p = 0.0328) as a result of unusually positive Cu isotope 




In brain tissue, the Cu isotope ratios vary between 0.9 and 2.2‰ for SOD1G93A, and 
between -1.3 to 2.2‰ for WT mice (Fig. 3B, Table 3) with the difference not reaching 
statistical significance. Across time, in both groups the isotope ratios decrease from 
1.8‰ at 30 d, to 1.3-1.4‰ at 120 d (Table 2; p = 0.011). 
 
Muscle 
In muscle tissue, the Cu isotope composition varies between -0.2 and 2.4‰ for 
SOD1G93A mice, and between -0.4 to 3.3‰ for WT animals (Fig. 3C). Similar to the 
trends observed in brain tissue, the isotope ratios decrease between 30-120 d, but this 




In whole blood the Cu isotope ratios vary between 0.6 and 1.9‰ for SOD1G93A, and 
between 0.5 and 1.4‰ for WT mice. These Cu isotope ratios fluctuate around 0.83‰, 
which is the isotope ratio of food (Fig. 4A). Overall there is no significant difference 
between SOD1G93A and WT mice. 
 
Food and Feces 
Mouse food samples have a Cu isotope ratio of 0.84 ± 0.03‰ (2SE, n=5), which is at 
the lower end of the observed values and similar to those observed in blood (Fig. 4A). 
The average Cu isotope ratio of all mouse feces samples is also 0.84 ± 0.59‰ (2SD, 
n=24), while SOD1G93A mouse feces average at 0.92 ± 0.66‰ (2SD, n=12) and WT 
mouse feces at 0.77 ± 0.48‰ (2SD, n=12) (Fig. 4B). There is no significant 
difference between the two populations or changes with time (Table 4). 
 
Table 4 – Metal concentrations (Cu, Fe, Zn) (µg g
-1 
± 2SD) and Cu isotope ratio (‰ ± 
2SD) in mouse feces 
time State δ
65
Cu  Cu Fe Zn n 
30 SOD1G93A 0.89 ± 0.42 53 ± 34 1210 ± 540 350 ± 170 3 
WT 0.67 ± 0.09 57 ±10 1270 ± 310 357 ± 8 3 
60 SOD1G93A 0.85 ± 0.29 85 ± 33 1470 ± 160 400 ± 51 3 
WT 0.94 ± 0.87 60 ± 21 1280 ± 210 320 ± 85 3 
90 SOD1G93A 1.19 ± 1.16 88 ± 18 1600 ± 530 410 ± 62 3 
WT 0.66 ± 0.33 90 ± 51 1600 ± 400 450 ± 33 3 
120 SOD1G93A 0.73 ± 0.35 90 ± 39 2000 ± 1500 400 ± 76 3 
WT 0.77 ± 0.24 61 ± 11 1620 ± 230 500 ± 570 3 
 
Discussion 
Accumulation of metals 
It has been previously hypothesized that changes in Cu and Zn concentrations play an 
important role in the gain-of-toxic function associated with mSOD1.
76,77
 This has 































































been supported by findings that (1) Cu chelators, such as D-penicillamine and 




 by reducing the overall 
available Cu, (2) the ATPase ATP7B, a Cu transporter, is down regulated in the spinal 
cord of SOD1 transgenic mice (G93A),
68
 (3) delivery of Cu via the blood-brain-
barrier permeable complex Diacetylbis(N(4)-methylthiosemicarbazonato) Copper(II) 
(Cu
II
(atsm)) to Cu-deficient SOD1 converted it to stable holo-SOD1 in the SOD1
G37R
 
mouse model, prolonging survival,
28
 suggesting a therapeutic target for increased Cu 
concentrations, and (4) Zn deficient mSOD1 can induce motor neuron apoptosis via 
peroxynitrite-mediated tyrosine nitration.
80
 Apart from these findings, Cu and Zn have 
an antagonistic interaction,
81
 meaning that dyshomeostasis of one could prevent the 
proper utilization of the other.
32
 Overexpression of mSOD1 (e.g. the SOD1
G93A
 mouse 
model of ALS used in this work) was proposed to lead to increased Cu concentrations 
in spinal cord tissue, due to a proposed increased affinity of mSOD1 for Cu, making it 
an effective Cu sink.
82
 However, a recent review
77
 concluded that partially metalated 
intermediate SOD1 species may account for the observed SOD1 toxic-gain of 
function. Taking this into account with an overall increased concentration of the 
mSOD1 in the SOD1
G93A
 model, Cu concentrations in ALS affected tissues are 
therefore expected to increase, compared to healthy controls. 
 
Spinal cord 
Overall, all metals (Cu, Zn, Fe), show a similar behavior: after a marked increase of 
Cu concentration from 30-60 d, the concentrations peak at 90 d, and decrease towards 
120 d, without significant differences between healthy and diseased tissues (Fig. 1A-
C). Lelie et al.
40
 found a redistribution of Cu between the gray and white spinal cord 
matter of SOD1
G93A
 mice, which may not be reflected in bulk analyses as performed 
in this study. Zinc concentrations are an exception as in the SOD1
G93A
 mouse they 
were found to keep increasing until 120 d. Furthermore, the WT tissue shows a 
marked rise from 60-90 d with unexpected high concentration of Zn at 90 d and then a 
decrease at 120 d. Recent findings
83
 suggest that the interaction between the Cu 
chaperone (CCS) and SOD1 is perturbed, such that, during the metalation and 
maturation of SOD1, the Zn atom is not incorporated properly into its structure. This 




 has found significantly elevated Cu concentrations in spinal cord 
tissue of several mouse models of ALS, which was suggested to be the result of 
mSOD1 in the SOD1
G93A
 mouse having a higher affinity to bind Cu ions, leading to 
increased Cu in spinal cord tissue compared to WT mice.
37
 However, recent work
84
 
did not find a significant difference between non transgenic WT and SOD1
G37R
 spinal 
cord tissue, similar to findings presented here (Fig. 1A). The previous observations of 
increased Cu concentrations, particularly in mouse models of ALS that involve over-
expression of SOD1, may therefore be reflective of the increased amount of SOD1 
expressed in these mice. It is further possible that this signal indicates the presence of 
free, but not bio-available, Cu, rather than a side effect of an increased binding 
affinity,
82
 as previously proposed. A recent review highlighted the increasing 
evidence for the involvement of partially metalated SOD1 in ALS development,
77
 
which is supported by work with SOD1
G37R
 mice whereby Cu was delivered directly 




 This direct delivery decreased the amount 
of metal deficient SOD1, while it improved the amount of fully metalated-SOD1 
present,
28





 and increased concentrations,
31,32,84
 in 































































various mSOD1 mouse model compared to controls. A lack of variation in Fe 
concentrations in the spinal cord in SOD1
G93A
 and WT over time and against one 







 and WT tissues had similar trends in all three metals, without there 
being a significant difference between the animal groups (Fig. 1D-F). A dramatic 
increase from 30 to 60 d, was followed by a slow decrease in Cu, Zn and Fe. The lack 
of difference between the SOD1
G93A
 and WT tissues suggests that these trends may be 
the result of ageing, which is only significant for Cu concentrations. While higher 





 our findings are in accordance with other work using mSOD1 mouse 
models (G37R, G93A, H46R/H48Q), where no differences were observed.
31,36,40
 This 
lack of increased concentrations, could be the result of a lack of an ALS-related up-
regulation of Cu trafficking to the cerebellum,
37
 and that only a small area of the brain 
is affected which may be difficult to detect when measuring the metal concentration 
in the whole brain.  
 
Muscle  
Muscle tissue from diseased mice consistently demonstrated higher metal 
concentrations than WT samples in accordance with previous findings,
84
 with 
increases in Cu and Zn concentrations preceding the establishment of symptoms (Fig. 
1G-H) and Fe trailing them (Fig. 1I). Skeletal muscle is one of the largest organs in 
the human body, comprising ~40% of the whole body lean mass; muscles and bones 
together contain ~50% of total body Cu.
86
 Muscle tissue provides a source for amino 
acids during stress and forms a crucial part of whole body metabolism and 
homeostasis,
87
 while also being suggested to contain a surplus of SOD.
88
 In ALS, 
muscle tissue,
89–91
 and other (neighboring) cell types
92
 may play a significant role in 
pathology development. Distinct and rapid muscle atrophy caused by MN death is a 
pathologic hallmark of ALS.  
 
The accumulation of excess Cu and Zn in muscle observed in this study could be the 
consequence of the over expression of the mSOD1 protein in the SOD1
G93A
 mouse, 
whereby the increased concentrations reflect an increased requirement for Cu and Zn 





. However, if the increases are not a consequence of the over-expression of 
SOD1 in this mouse model, they may indicate a causal pathologic feature of ALS, 
whereby accumulation of Cu and Zn in muscle could be toxic, resulting in MN death. 
This would support the dying-back-hypothesis
93
: ALS may be a dying back motor 
neuropathy whereby distal axonal degeneration occurs and this precedes neuronal 
degeneration.
94,95
 The axon and neuromuscular junction are affected at an earlier stage 
prior to the onset of symptoms and neurodegeneration, which may indicate that 
intrinsic defects in the muscle occur early, promoting or contributing to withdrawal of 
the motor axon.
96
 Signaling between the muscle and the neuron is important for 
axonal growth and management of the neuromuscular junction,
97
 while the loss of 
signal from the neuron to the muscle leads to atrophy. It is also possible that muscle 
defects may be independent of axonal withdrawal,
96
 leading to the assumption that 
skeletal muscle is likely to be one of the primary targets of ALS-associated mutations. 
While the origin of the here-observed accumulating metals remains unknown, Cu 
isotope analyses (see below) suggest that the Cu could originate from a dietary, 































































exogenic Cu source, however, the direction of and magnitude of changes (increase of 
influx vs decrease of efflux vs changes to recycling processes) are unclear. 
 
Whole blood 
There were no significant trends in metal concentrations of Cu and Zn in whole blood 
over time or between the SOD1
G93A
 and WT samples. Iron concentrations are an 
exception, as they follow a trend over time such that the concentration decreases 
between 30-60 d and then increases until 120 d (Fig. 2A-C). Mixed results have been 
documented for Cu concentrations in blood serum and ceruloplasmin: concentrations 
have been reported to be decreased in ALS patients, compared to healthy controls,
98,99
 
or to not be significantly different
100
, similar to the here presented data. This may be a 
side effect of the short residence time of these metals in blood (e.g. 7-14 d for Cu in 
mice
101
), robust excretion mechanisms,
101
 and low Cu concentration compared to 
humans.
101,102
 These may therefore account for the lack of positive association with 
disease progression. One study on human blood reported a positive association 





Feces samples did not demonstrate a difference between SOD1
G93A
 and WT samples, 
for any of the assessed metals. For Fe and Cu, a time dependent increase in 
concentration was found, which is most likely the result of the higher dietary 
requirement of the larger mice. Overall, no disease dependent anomalies of metal 
uptake or excretion were detected. 
 
Copper isotope ALS signal 
The Cu isotopes display a scattered pattern for spinal cord tissue without any clear 
trends (Fig. 3A). Brain (Fig. 3B) and muscle tissue (Fig. 3C) follow a similar time-
dependent trend, whereby isotope ratios start at a more positive value at 30 d and then 
shift towards less positive values. The same trend was observed in SOD1
G93A
 and WT 
tissues. In blood (Fig. 4A), no significant difference was detected between SOD1
G93A
 
and WT. It was observed, however, that the blood and feces isotope ratios (Fig. 4) 
fluctuate around 0.84‰, i.e. the value of food, indicating that the isotope signal is 
more a reflection of the diet than the disease. Overall, the isotope ratios from tissues 
from the SOD1
G93A
 mouse model of ALS presented here indicate that there is no 
presence of a clear ALS-associated Cu isotope signal.  
 
It has been postulated that stable isotope ratios can inform about past oxidation 
conditions in geological and biological systems.
104





 change in association with cancer development and Cu isotope ratios with liver 
cirrhosis.
64
 In the example of cancer, hypoxic (reducing) conditions within the 
tumor’s environment can impair the metabolism of Cu and change the metal’s redox 
state. This is the consequence of the binding ability of specific molecules, inducing 




A variety of neurodegenerative diseases have been associated with excessive 
oxidative stress
106–110
 including ALS where oxidative stress has been identified to be 
of great importance,
111
 in both humans and rodent models.
112
 Two mechanisms have 
been identified to induce oxidative stress in cells in relation to Cu: (1) a Fenton-like 
reaction that can directly catalyze reactive oxygen species (ROS) generation,
113
 (2) 
exposure to elevated concentrations of Cu, which significantly decreases the levels of  

































































 A decrease in GSH limits the cell’s antioxidant ability, 
contributing to shifting the redox balance towards more oxidizing conditions.
18,88
 This 
may also enhance the cytotoxicity of ROS and allow Cu to be more catalytically 
active, resulting in the production of even more ROS.
116
 In ALS, mitochondrial 
dysfunction was reportedly responsible for increases in the free radical 
generation,
109,117,118
 followed by oxidative stress and associated calcium toxicity 
following glutamate receptor activation.
118
 As a result, it was expected that there 
should be a direct correlation between disease progression and the development of 
oxidative stress,
119,120
 leading to Cu isotope fractionation, and an ALS-associated Cu 
isotope signal.  
 
The observed lack of a Cu isotope signal in the SOD1
G93A
 mouse model of ALS may 
be the result of several factors. First, ROS production does increase as a function of 
time (ageing-effect) in SOD1 transgenic mice,
121
 which would require ROS to be 
relatively more increased to be able to be traced as a deviation of the signal that arises 
from ageing alone. Second, in the spinal cord of the SOD1
G93A
 mice two 
metallothionein-I/II (MT-I/II) isoforms were previously found to be significantly 
elevated, which act as Cu chaperones, sequestering free Cu
122
 as a compensatory 
reaction to Cu-mediated oxidative stress, even at pre-symptomatic stages.
36
 It was 
later found that overexpression of MT-I in the SOD1
G93A
 mouse model prolongs 
survival and restores Cu dyshomeostasis,
33
 which suggests that ROS production could 
be regulated and a resulting Cu isotope signal dampened.  
 
Finally, it is widely accepted that it is not the loss of antioxidant function of mSOD1 
that leads to the development of pathology, but rather a separate toxic gain-of-
function.
9
 While this toxic gain-of-function was confirmed by transgenic mice 
overexpressing mSOD1, where the level of mSOD1-expression was proportional to 
the onset and severity of symptoms,
8,123,124
 it has proved difficult to elucidate the 
specific mechanisms of mSOD1 toxicity.
77
 Given that the ALS-like phenotype of the 
SOD1
G93A
 mice used in this study is driven by the expression of the mSOD1 and to a 
lesser extend its over expression, it is reasonable to assume that the inferred oxidative 
stress would not be reflected in a changed isotope signature in the target tissues. 
When taking into account that in brain and spinal cord tissue there is little to no 
difference in Cu concentrations between SOD1
G93A
 and WT tissue (Fig. 1A, D), this 
suggests that, in addition to the tight control of Cu influx through the blood-brain-
barrier,
88,125
 the binding of Cu to various proteins/binding sites not does alter as a 
result of the disease. The alteration may further be too subtle to be detected using 
stable isotope techniques at the currently available resolution. Changes in Cu 
concentration in tissues may be attributable to the overall higher concentration of 
mSOD1 in the transgenic mice or the up-regulation of cupro-proteins as a side effect 
of mSOD1 overexpression, possibly leading to cell specific deficiencies of Cu, 
resulting in no change to the isotope ratio in the tissue.  
 
The significantly elevated Cu concentrations in SOD1
G93A
 muscle tissue (Fig. 1G) 
offer a slightly different picture: muscle tissue, compared to central nervous system 
tissues, is subject to less stringent regulation of Cu transport.
88
 Muscle tissue in 
general was noted to be a major repository of metals, and contains a surplus of 
SOD1.
88
 A tracer study using 
64
Cu observed that young (neonates, 10-12 d) mice 
retained significantly more Cu than adult counterparts in muscle tissue.
126
 We 
hypothesize that muscle tissue may, at least in part, serve as a reservoir for exogenic, 































































dietary Cu, and its natural Cu isotope signature may, therefore, alter to become more 
similar to that of the food source over time (30 – 90 d) (Fig. 3C). Further to the 
assimilation, it is plausible to assume that recycling processes can further enhance the 
preferential uptake and retention of the lighter Cu isotope over time, indicating that 
Cu may accumulate in the weaker bonds
56,57
. While there is overall more Cu in the 
SOD1
G93A
 muscle tissue (Fig. 1D), it binds to the same protein binding sites as in the 
WT controls. This is supported by the Cu isotope ratios measured in this work (Fig. 
3C) whereby the ratios move in the same direction in SOD1
G93A
 and WT mice. 
However, SOD1
G93A
 tissue appears to follow a steeper decline towards the isotope 
ratio of food (0.84‰), suggesting that cupro-proteins, using weaker bonds, may be 
up-regulated and accumulate Cu, as previously suggested for several other tissues.
29,37
 
This accumulation of Cu could then lead to a dying backward process, in the form of 




Cu isotope ageing signal 
The Cu isotope ratios for muscle and brain tissue in this study demonstrate a similar 
age-dependent trend, which is independent of disease state. The Cu isotope 
compositions are positive at 30 d (~2‰) and then decrease over time (Fig. 3B and C). 
It is well known that organisms accumulate certain metals in various tissues and fluids 
over the course of their lifespan.
19,128,129
 As the oldest mice tested in this study were 
120 d old (still comparatively young, equivalent to ≈ 20-30 y in humans
130
), it is 
surprising that a Cu isotope ageing-signal may already be present. The downward 
trends are more pronounced in muscle than in the brain, which could be a result of the 
different rates of metabolism in these different organs, as observed in humans, where 
female breast tissue ages faster than other organs.
131
 A precise assessment of ageing in 
individual organs remains difficult. 
 
In order to determine whether the signal observed here is indicative of ageing, it is 
important to control for any potential age-related changes in Cu absorption that may 
affect the signal. In men and women between 20 and 83 y, there is no significant 
change in Cu absorption over time
132
 and Cu absorption is tightly regulated as a 
function of available dietary Cu.
133
 As the mice used in this study (and their parents 
before them) were given a uniform and standardized diet, it is reasonable to assume 
that trends over time are a true expression of ageing, rather than the result of 
variability in diet with age.  
 
It is well known that during mammal pregnancy, metals (nutrients) are transported 
from the mother across the placenta to the fetus, where they cross the fetal 
endothelium and enter circulation (Fig. 5).
134
 These metals (e.g. Fe and Cu) are then 
stored in the fetal liver and are rapidly liberated to facilitate growth after birth.
88,135,136
 
Copper transport to the fetus increases in the last trimester and is chaperone 
specific.
137
 The Cu accumulates in the placenta in the form of ceruloplasmin, CuHis2, 
or other low molecular complexes.
138
 In absence of ceruloplasmin, Cu transport is not 
inhibited, highlighting the potential importance of the CuHis2 pathway in the 
transport.
134
 Based on ab initio calculations, histidine containing compounds, such as 
ceruloplasmin and CuHis2 [Cu
2+
(His)2] have previously been hypothesized to 
concentrate the heavier isotope of Cu.
58
 In this study, more positive Cu isotope ratios 
(accumulation of heavier isotopes) in brain and muscle samples (Fig. 3B and C) were 
found at 30 d. These results suggest the presence of a ‘starting pool’ of ‘heavy’ Cu 
received from the mother, which is then diluted, recycled or changed over time 





































































The assessment of metal concentrations in tissues from healthy and ALS mice yielded 
contrasting results. Brain and blood samples showed no definitive trends between 
diseased and healthy tissues, while Zn concentrations in spinal cord and muscle tissue, 
and Cu concentrations in muscle tissue were elevated at pre-symptomatic stages in the 
diseased tissues. An increase in Fe concentrations in muscle trailed the development 
of symptoms. Observed pre-symptomatic changes in metal concentrations in the 
results from muscle tissue may support the dying-back hypothesis as a function of 
toxicity induced by the accumulation. This warrants further investigation into the 
potential applicability of metal concentrations as biomarkers for ALS. Copper isotope 
ratios revealed no clear disease-based signal in any of the tissues. When considering 
the higher Cu concentrations and changes in isotope ratios in the SOD1 mouse 
muscle, it could suggest that either the association of Cu with specific binding sites 
does not change or that possible changes in the association of Cu with other binding 
sites is below the detection limit of the applied method. Future studies should consider 
overcoming the limitations of the mSOD1 over expression models by using transgenic 
mice, which over express wild type SOD1. This way effects induced by the increased 
expression of SOD1 can be accounted for. 
 
In muscle and brain tissue, changes in isotope composition over time were observed, 
suggesting the presence of an ageing signal. This potentially presents a new way of 
looking at the concept of metabolic ageing, whereby the speed of ageing can be 
determined by turn-over rates of recycling and accumulation processes of Cu in 
certain tissues, as a deviation from the fetal Cu pool. Mice currently present one of the 
best model organisms to study ALS and ageing. A promising direction for future 
studies is the application of metal concentration and Cu isotope measurements to 
human samples, including blood plasma and potential muscle biopsies, and to specific 




The authors want to thank Michael Ellwood (Research School of Earth Sciences, the 
Australian National University) for providing a NIST-976 solution. Luke McAlary is 
thanked for useful discussion, Andrew Zammit Mangion for guidance in the data pre-
processing and James P. Dawber with the statistical analysis. Philip Doble and the 
University of Technology, Sydney granted TGE visitor status to perform some of the 
microwave digestion work at their facilities. This work was funded by Australian 
Research Council Discovery grant DP140100354 and a SMAH Small Project grant. 
TGE acknowledges a Discovery University Postgraduate Award.  
  
































































1 R. L. Redler and N. V Dokholyan, Prog. Mol. Biol. Transl. Sci., 2012, 107, 
215–62. 
2 L. P. Rowland and N. A. Shneider, N. Engl. J. Med., 2001, 344, 1688–1700. 
3 O. Hardiman, L. H. van den Berg and M. C. Kiernan, Nat. Rev. Neurol., 2011, 
7, 639–649. 
4 W. Robberecht and T. Philips, Nat. Rev. Neurosci., 2013, 14, 248–264. 
5 D. R. Rosen, T. Siddique, D. Patterson, D. A. Figlewicz, P. Sapp, A. Hentati, 
D. Donaldson, J. Goto, J. P. O’Regan, H.-X. Deng, Z. Rahmani, A. Krizus, D. 
McKenna-Yasek, A. Cayabyab, S. M. Gaston, R. Berger, R. E. Tanzi, J. J. 
Halperin, B. Herzfeldt, R. Van den Bergh, W.-Y. Hung, T. Bird, G. Deng, D. 
W. Mulder, C. Smyth, N. G. Laing, E. Soriano, M. A. Pericak–Vance, J. 
Haines, G. A. Rouleau, J. S. Gusella, H. R. Horvitz and R. H. Brown, Nature, 
1993, 362, 59–62. 
6 P. M. Andersen, Curr. Neurol. Neurosci. Rep., 2006, 6, 37–46. 
7 M. Cozzolino, A. Ferri and M. T. Carrì, Antioxid. Redox Signal., 2008, 10, 
405–443. 
8 M. Gurney, H. Pu, A. Chiu, M. Dal Canto, C. Polchow, D. Alexander, J. 
Caliendo, A. Hentati, Y. Kwon, H. Deng and A. Et, Science (80-. )., 1994, 264, 
1772–1775. 
9 L. I. Bruijn, M. K. Houseweart, S. Kato, K. L. Anderson, S. D. Anderson, E. 
Ohama, A. G. Reaume, R. W. Scott and D. W. Cleveland, Science, 1998, 281, 
1851–4. 
10 L. I. Bruijn, M. W. Becher, M. K. Lee, K. L. Anderson, N. A. Jenkins, N. G. 
Copeland, S. S. Sisodia, J. D. Rothstein, D. R. Borchelt, D. L. Price and D. W. 
Cleveland, Neuron, 1997, 18, 327–38. 
11 M. E. Ripps, G. W. Huntley, P. R. Hof, J. H. Morrison and J. W. Gordon, Proc. 
Natl. Acad. Sci. U. S. A., 1995, 92, 689–93. 
12 S. Saxena, E. Cabuy and P. Caroni, Nat. Neurosci., 2009, 12, 627–36. 
13 M. T. Carri, A. Battistoni, F. Polizio, A. Desideri and G. Rotilio, FEBS Lett., 
1994, 356, 314–6. 
14 W. S. Eum and J. H. Kang, Mol. Cells, 1999, 9, 110–4. 
15 L. J. Hayward, J. a Rodriguez, J. W. Kim, A. Tiwari, J. J. Goto, D. E. Cabelli, 
J. S. Valentine and R. H. Brown, J. Biol. Chem., 2002, 277, 15923–31. 
16 L. Gaetke, Toxicology, 2003, 189, 147–163. 
17 M. Valko, H. Morris and M. Cronin, Curr. Med. Chem., 2005, 12, 1161–1208. 
18 K. Jomova and M. Valko, Toxicology, 2011, 283, 65–87. 
19 D. Hare, S. Ayton, A. Bush and P. Lei, Front. Aging Neurosci., 2013, 5, 34. 
20 H. Tapiero, D. M. Townsend and K. D. Tew, Biomed. Pharmacother., 2003, 
57, 386–398. 
21 K. M. Davies, S. Bohic, A. Carmona, R. Ortega, V. Cottam, D. J. Hare, J. P. M. 
Finberg, S. Reyes, G. M. Halliday, J. F. B. Mercer and K. L. Double, 
Neurobiol. Aging, 2014, 35, 858–866. 
22 F. Larner, B. Sampson, M. Rehkämper, D. J. Weiss, J. R. Dainty, S. 
O’Riordan, T. Panetta and P. G. Bain, Metallomics, 2013, 5, 125. 
23 P. Dusek, P. M. Roos, T. Litwin, S. A. Schneider, T. P. Flaten and J. Aaseth, J. 
Trace Elem. Med. Biol., 2015, 31, 193–203. 
24 M. a Greenough, J. Camakaris and A. I. Bush, Neurochem. Int., 2013, 62, 540–
55. 
25 E. House, M. Esiri, G. Forster, P. G. Ince and C. Exley, Metallomics, 2012, 4, 
































































26 D. Kaden, A. I. Bush, R. Danzeisen, T. A. Bayer and G. Multhaup, Int. J. 
Alzheimers. Dis., 2011, 2011, 345614. 
27 D. Shore, R. I. Henkin, N. R. Nelson, R. P. Agarwal and R. J. Wyatt, J. Am. 
Geriatr. Soc., 1984, 32, 892–895. 
28 B. R. Roberts, N. K. H. Lim, E. J. McAllum, P. S. Donnelly, D. J. Hare, P. a 
Doble, B. J. Turner, K. a Price, S. Chun Lim, B. M. Paterson, J. L. Hickey, T. 
W. Rhoads, J. R. Williams, K. M. Kanninen, L. W. Hung, J. R. Liddell, A. 
Grubman, J.-F. Monty, R. M. Llanos, D. R. Kramer, J. F. B. Mercer, A. I. 
Bush, C. L. Masters, J. a Duce, Q.-X. Li, J. S. Beckman, K. J. Barnham, A. R. 
White and P. J. Crouch, J. Neurosci., 2014, 34, 8021–8031. 
29 P. M. Roos, O. Vesterberg, T. Syversen, T. P. Flaten and M. Nordberg, Biol. 
Trace Elem. Res., 2013, 151, 159–70. 
30 I. Hozumi, T. Hasegawa, A. Honda, K. Ozawa, Y. Hayashi, K. Hashimoto, M. 
Yamada, A. Koumura, T. Sakurai, A. Kimura, Y. Tanaka, M. Satoh and T. 
Inuzuka, J. Neurol. Sci., 2011, 303, 95–99. 
31 Q.-X. Li, S. S. Mok, K. M. Laughton, C. a McLean, I. Volitakis, R. a Cherny, 
N. S. Cheung, A. R. White and C. L. Masters, Aging Cell, 2006, 5, 153–65. 
32 E. Tokuda, E. Okawa, S. Watanabe, S.-I. Ono and S. L. Marklund, Neurobiol. 
Dis., 2013, 54, 308–319. 
33 E. Tokuda, E. Okawa, S. Watanabe and S.-I. Ono, Hum. Mol. Genet., 2014, 23, 
1271–85. 
34 E. Tokuda, S. Watanabe, E. Okawa and S. Ono, Neurotherapeutics, 2015, 12, 
461–476. 
35 E. Tokuda, S. Ono, K. Ishige, S. Watanabe, E. Okawa, Y. Ito and T. Suzuki, 
Exp. Neurol., 2008, 213, 122–8. 
36 E. Tokuda, S. I. Ono, K. Ishige, A. Naganuma, Y. Ito and T. Suzuki, 
Toxicology, 2007, 229, 33–41. 
37 E. Tokuda, E. Okawa and S. I. Ono, J. Neurochem., 2009, 111, 181–191. 
38 M. W. Bourassa, H. H. Brown, D. R. Borchelt, S. Vogt and L. M. Miller, 
Front. Aging Neurosci., 2014, 6, 1–6. 
39 M. W. Bourassa and L. M. Miller, Metallomics, 2012, 4, 721. 
40 H. L. Lelie, A. Liba, M. W. Bourassa, M. Chattopadhyay, P. K. Chan, E. B. 
Gralla, L. M. Miller, D. R. Borchelt, J. S. Valentine and J. P. Whitelegge, J. 
Biol. Chem., 2011, 286, 2795–2806. 
41 T. N. T. Dang, N. K. H. Lim, A. Grubman, Q.-X. Li, I. Volitakis, A. R. White 
and P. J. Crouch, Front. Aging Neurosci., 2014, 6, 15. 
42 K. Ikeda, T. Hirayama, T. Takazawa, K. Kawabe and Y. Iwasaki, Intern. Med., 
2012, 51, 1501–1508. 
43 Y. Nadjar, P. Gordon, P. Corcia, G. Bensimon, L. Pieroni, V. Meininger and F. 
Salachas, PLoS One, 2012, 7, 2–7. 
44 X. W. Su, S. L. Clardy, H. E. Stephens, Z. Simmons and J. R. Connor, 
Amyotroph. Lateral Scler. Front. Degener., 2015, 16, 102–107. 
45 E. F. Goodall, M. S. Haque and K. E. Morrison, J. Neurol., 2008, 255, 1652–
1656. 
46 C. Langkammer, C. Enzinger, S. Quasthoff, P. Grafenauer, M. Soellinger, F. 
Fazekas and S. Ropele, J. Magn. Reson. Imaging, 2010, 31, 1339–1345. 
47 J. Y. Kwan, S. Y. Jeong, P. van Gelderen, H. X. Deng, M. M. Quezado, L. E. 
Danielian, J. A. Butman, L. Chen, E. Bayat, J. Russell, T. Siddique, J. H. Duyn, 
T. A. Rouault and M. K. Floeter, PLoS One, 2012, 7. 































































48 A. Ignjatović, Z. Stević, S. Lavrnić, M. Daković and G. Bačić, J. Magn. Reson. 
Imaging, 2013, 38, 1472–1479. 
49 A. Ignjatović, Z. Stević, D. Lavrnić, A. Nikolić-Kokić, D. Blagojević, M. 
Spasić and I. Spasojević, Amyotroph. Lateral Scler., 2012, 13, 357–362. 
50 S. Oshiro, M. S. Morioka and M. Kikuchi, Adv. Pharmacol. Sci., 2011, 2011, 
1–8. 
51 T. D. B. Lyon and G. S. Fell, J. Anal. At. Spectrom., 1990, 5, 135. 
52 T. D. B. Lyon, S. Fletcher, G. S. Fell and M. Patriarca, Microchem. J., 1996, 
54, 236–245. 
53 J. R. Turnlund, M. C. Michel, W. R. Keyes, Y. Schutz and S. Margen, Am. J. 
Clin. Nutr., 1982, 36, 587–91. 
54 J. R. Turnlund, W. R. Keyes, H. L. Anderson and L. L. Acord, Am. J. Clin. 
Nutr., 1989, 49, 870–8. 
55 L. J. Harvey, J. R. Dainty, W. J. Hollands, V. J. Bull, J. H. Beattie, T. I. 
Venelinov, J. A. Hoogewerff, I. M. Davies and S. J. Fairweather-Tait, Use of 
mathematical modeling to study copper metabolism in humans., 2005, vol. 81. 
56 F. Albarède, Elements, 2015, 11, 265–269. 
57 J. Bigeleisen and M. G. Mayer, J. Chem. Phys., 1947, 15, 261. 
58 V. Balter, A. Lamboux, A. Zazzo, P. Télouk, Y. Leverrier, J. Marvel, A. P. 
Moloney, F. J. Monahan, O. Schmidt and F. Albarède, Metallomics, 2013, 5, 
1470. 
59 V. Balter, A. Nogueira da Costa, V. P. Bondanese, K. Jaouen, A. Lamboux, S. 
Sangrajrang, N. Vincent, F. Fourel, P. Télouk, M. Gigou, C. Lécuyer, P. 
Srivatanakul, C. Bréchot, F. Albarède and P. Hainaut, Proc. Natl. Acad. Sci., 
2015, 112, 982–985. 
60 F. Albarede, P. Télouk, V. Balter, V. P. Bondanese, E. Albalat, P. Oger, P. 
Bonaventura, P. Miossec and T. Fujii, Metallomics, 2016, 8, 1056–1070. 
61 J. L. L. Morgan, G. W. Gordon, R. C. Arrua, J. L. Skulan, A. D. Anbar and T. 
D. Bullen, Anal. Chem., 2011, 83, 6956–6962. 
62 J. L. L. Morgan, J. L. Skulan, G. W. Gordon, S. J. Romaniello, S. M. Smith and 
A. D. Anbar, Proc. Natl. Acad. Sci., 2012, 109, 9989–9994. 
63 P. Télouk, A. Puisieux, T. Fujii, V. Balter, V. P. Bondanese, A.-P. Morel, G. 
Clapisson, A. Lamboux and F. Albarede, Metallomics, 2015, 7, 299–308. 
64 M. Costas-Rodríguez, Y. Anoshkina, S. Lauwens, H. Van Vlierberghe, J. 
Delanghe and F. Vanhaecke, Metallomics, 2015, 7, 491–498. 
65 F. Larner, L. N. Woodley, S. Shousha, A. Moyes, E. Humphreys-Williams, S. 
Strekopytov, A. N. Halliday, M. Rehkämper and R. C. Coombes, Metallomics, 
2015, 7, 112–117. 
66 F. Larner, S. Shousha and R. C. Coombes, Biomark. Med., 2015, 9, 379–382. 
67 M. Costas-Rodríguez, J. Delanghe and F. Vanhaecke, TrAC Trends Anal. 
Chem., 2016, 76, 182–193. 
68 M. K. Olsen, S. L. Roberds, B. R. Ellerbrock, T. J. Fleck, D. K. McKinley and 
M. E. Gurney, Ann. Neurol., 2001, 50, 730–40. 
69 T. G. Enge, M. P. Field, D. F. Jolley, H. Ecroyd, M. H. Kim and A. Dosseto, J. 
Anal. At. Spectrom., 2016, 31, 2023–2030. 
70 F. Larner, M. Rehkämper, B. J. Coles, K. Kreissig, D. J. Weiss, B. Sampson, C. 
Unsworth and S. Strekopytov, J. Anal. At. Spectrom., 2011, 26, 1627. 
71 D. C. Baxter, I. Rodushkin, E. Engström and D. Malinovsky, J. Anal. At. 
Spectrom., 2006, 21, 427. 
72 S. G. Nielsen, M. Rehkämper, J. Baker and A. N. Halliday, Chem. Geol., 2004, 
































































73 X. K. Zhu, R. K. O’Nions, Y. Guo, N. S. Belshaw and D. Rickard, Chem. 
Geol., 2000, 163, 139–149. 
74 R Core Team, 2016. 
75 D. J. Barr, R. Levy, C. Scheepers and H. J. Tily, J. Mem. Lang., 2013, 68, 255–
278. 
76 D. R. Borchelt, M. K. Lee, H. S. Slunt, M. Guarnieri, Z. S. Xu, P. C. Wong, R. 
H. Brown, D. L. Price, S. S. Sisodia and D. W. Cleveland, Proc. Natl. Acad. 
Sci. U. S. A., 1994, 91, 8292–6. 
77 J. B. Hilton, A. R. White and P. J. Crouch, J. Mol. Med., 2015, 93, 481–487. 
78 A. F. Hottinger, E. G. Fine, M. E. Gurney, A. D. Zurn and P. Aebischer, Eur. J. 
Neurosci., 1997, 9, 1548–1551. 
79 S. Nagano, Y. Fujii, T. Yamamoto, M. Taniyama, K. Fukada, T. Yanagihara 
and S. Sakoda, Exp. Neurol., 2003, 179, 176–80. 
80 A. G. Estévez, J. P. Crow, J. B. Sampson, C. Reiter, Y. Zhuang, G. J. 
Richardson, M. M. Tarpey, L. Barbeito and J. S. Beckman, Science, 1999, 286, 
2498–500. 
81 N. T. Davies and T. Davies, Proc Nutr Soc, 1974, 33, 293–298. 
82 E. Tokuda and Y. Furukawa, Int. J. Mol. Sci., 2016, 17, 636. 
83 G. S. A. Wright, S. V. Antonyuk and S. S. Hasnain, Sci. Rep., 2016, 6, 27691. 
84 J. B. Hilton, A. R. White and P. J. Crouch, Metallomics, 2016, 8, 1002–1011. 
85 E. J. McAllum, N. K.-H. Lim, J. L. Hickey, B. M. Paterson, P. S. Donnelly, Q.-
X. Li, J. R. Liddell, K. J. Barnham, A. R. White and P. J. Crouch, Amyotroph. 
Lateral Scler. Frontotemporal Degener., 2013, 14, 586–90. 
86 G. W. Evans, Physiol. Rev., 1973, 53, 535–70. 
87 B. A. Neel, Y. Lin and J. E. Pessin, Trends Endocrinol. Metab., 2013, 24, 635–
643. 
88 M. C. Linder, Biochemistry of Copper, Springer US, Boston, MA, 1991. 
89 G. Luo, J. Yi, C. Ma, Y. Xiao, F. Yi, T. Yu and J. Zhou, PLoS One, 2013, 8, 
e82112. 
90 J.-L. Gonzalez de Aguilar, C. Niederhauser-Wiederkehr, B. Halter, M. De 
Tapia, F. Di Scala, P. Demougin, L. Dupuis, M. Primig, V. Meininger and J.-P. 
Loeffler, Physiol. Genomics, 2008, 32, 207–218. 
91 Y. Xiao, C. Ma, J. Yi, S. Wu, G. Luo, X. Xu, P.-H. Lin, J. Sun and J. Zhou, 
Physiol. Rep., 2015, 3, e12271–e12271. 
92 S. Boillée, C. Vande Velde and D. Cleveland, Neuron, 2006, 52, 39–59. 
93 M. C. Kiernan, S. Vucic, B. C. Cheah, M. R. Turner, A. Eisen, O. Hardiman, J. 
R. Burrell and M. C. Zoing, Lancet, 2011, 377, 942–55. 
94 L. R. Fischer, D. G. Culver, P. Tennant, A. a. Davis, M. Wang, A. Castellano-
Sanchez, J. Khan, M. a. Polak and J. D. Glass, Exp. Neurol., 2004, 185, 232–
40. 
95 D. Frey, C. Schneider, L. Xu, J. Borg, W. Spooren and P. Caroni, J. Neurosci., 
2000, 20, 2534–42. 
96 J. Zhou, J. Yi and L. Bonewald, Curr. Osteoporos. Rep., 2015, 13, 274–279. 
97 Q. T. Nguyen, Y. J. Son, J. R. Sanes and J. W. Lichtman, J. Neurosci., 2000, 
20, 6077–86. 
98 T. Domzał and B. Radzikowska, Neurol. Neurochir. Pol., 1983, 17, 343–6. 
99 E. Kapaki, C. Zournas, G. Kanias, T. Zambelis, A. Kakami and C. 
Papageorgiou, J. Neurol. Sci., 1997, 147, 171–175. 
100 R. Pamphlett, R. McQuilty and K. Zarkos, Neurotoxicology, 2001, 22, 401–
































































101 A. Cabrera, E. Alonzo, E. Sauble, Y. L. Chu, D. Nguyen, M. C. Linder, D. S. 
Sato and A. Z. Mason, BioMetals, 2008, 21, 525–543. 
102 A. Montaser, C. Tetreault and M. Linder, Exp. Biol. Med., 1992, 200, 321–329. 
103 T. L. Peters, J. D. Beard, D. M. Umbach, K. Allen, J. Keller, D. Mariosa, D. P. 
Sandler, S. Schmidt, F. Fang, W. Ye and F. Kamel, Neurotoxicology, 2016, 54, 
119–126. 
104 E. A. Schauble, Rev. Mineral. Geochemistry, 2004, 55, 65–111. 
105 V. P. Bondanese, A. Lamboux, M. Simon, J. Lafont, E. Albalat, S. Pichat, J.-
M. Vanacker, P. Télouk, V. Balter, P. Oger and F. Albarède, Metallomics, 
2016. 
106 R. J. Ferrante, S. E. Browne, L. A. Shinobu, A. C. Bowling, M. J. Baik, U. 
MacGarvey, N. W. Kowall, R. H. Brown and M. F. Beal, J. Neurochem., 1997, 
69, 2064–74. 
107 E. Gordillo, A. Ayala, J. Bautista and A. Machado, J. Biol. Chem., 1989, 264, 
17024–8. 
108 J. M. Matés and F. Sánchez-Jiménez, Front. Biosci., 1999, 4, D339-45. 
109 L. M. Sayre, M. A. Smith and G. Perry, Curr. Med. Chem., 2001, 8, 721–38. 
110 E. Stadtman, Science (80-. )., 1992, 257, 1220–1224. 
111 I. Niebrój-Dobosz, D. Dziewulska and H. Kwieciński, Folia Neuropathol., 
2004, 42, 151–6. 
112 L. Ferraiuolo, J. Kirby, A. J. Grierson, M. Sendtner and P. J. Shaw, Nat. Rev. 
Neurol., 2011, 7, 616–630. 
113 J. Prousek, Pure Appl. Chem., 2007, 79. 
114 H. Speisky, M. Gómez, F. Burgos-Bravo, C. López-Alarcón, C. Jullian, C. 
Olea-Azar and M. E. Aliaga, Bioorg. Med. Chem., 2009, 17, 1803–10. 
115 M. D. Mattie and J. H. Freedman, Am. J. Physiol. Cell Physiol., 2004, 286, 
C293-301. 
116 A. Ahuja, K. Dev, R. S. Tanwar, K. K. Selwal and P. K. Tyagi, J. Trace Elem. 
Med. Biol., 2015, 29, 11–23. 
117 L. Siklós, J. I. Engelhardt, M. E. Alexianu, M. E. Gurney, T. Siddique and S. 
H. Appel, J. Neuropathol. Exp. Neurol., 1998, 57, 571–87. 
118 R. H. Swerdlow, J. K. Parks, G. Pattee and  w davis P. Jr, Amyotroph. Lateral 
Scler. Other Mot. Neuron Disord., 2000, 1, 185–190. 
119 S. C. Barber, R. J. Mead and P. J. Shaw, Biochim. Biophys. Acta - Mol. Basis 
Dis., 2006, 1762, 1051–1067. 
120 S. C. Barber and P. J. Shaw, Free Radic. Biol. Med., 2010, 48, 629–41. 
121 R. Liu, J. S. Althaus, B. R. Ellerbrock, D. A. Becker and M. E. Gurney, Ann. 
Neurol., 1998, 44, 763–70. 
122 J. R. Prohaska and A. A. Gybina, J. Nutr., 2004, 134, 1003–6. 
123 P. C. Wong, C. a Pardo, D. R. Borchelt, M. K. Lee, N. G. Copeland, N. a 
Jenkins, S. S. Sisodia, D. W. Cleveland and D. L. Price, Neuron, 1995, 14, 
1105–16. 
124 A. Henriques, C. Pitzer and A. Schneider, PLoS One, 2010, 5, e15445. 
125 B.-S. Choi and W. Zheng, Brain Res., 2009, 1248, 14–21. 
126 J. R. Mann, J. Camakaris and D. M. Danks, Biochem. J., 1979, 180, 613–9. 
127 M. Wong and L. J. Martin, Hum. Mol. Genet., 2010, 19, 2284–302. 
128 H. Basun, L. G. Forssell, L. Wetterberg and B. Winblad, J. Neural Transm. 
Park. Dis. Dement. Sect., 1991, 3, 231–258. 
129 L. Zecca, M. Gallorini, V. Schünemann, A. X. Trautwein, M. Gerlach, P. 































































Riederer, P. Vezzoni and D. Tampellini, J. Neurochem., 2001, 76, 1766–1773. 
130 K. Flurkey, J. McCurrer and D. Harrison, in The Mouse in Biomedical 
Research, Elsevier, 2007, pp. 637–672. 
131 S. Horvath, Genome Biol., 2013, 14, R115. 
132 P. E. Johnson, D. B. Milne and G. I. Lykken, Am. J. Clin. Nutr., 1992, 56, 917–
25. 
133 J. R. Turnlund, Am. J. Clin. Nutr., 1998, 67, 960S–964S. 
134 L. Gambling, R. Danzeisen, C. Fosset, H. S. Andersen, S. Dunford, S. K. S. 
Srai and H. J. MCArdle, J. Nutr., 2003, 133, 1554S–6S. 
135 S. a Donley, B. J. Ilagan, H. Rim and M. C. Linder, Am. J. Physiol. Endocrinol. 
Metab., 2002, 283, E667–E675. 
136 R. Uauy, M. Olivares and M. Gonzalez, Am. J. Clin. Nutr., 1998, 67, 952S–
959S. 
137 K. K. Tong and H. J. McArdle, Biochim. Biophys. Acta - Mol. Cell Res., 1995, 
1269, 233–236. 
138 H. J. McArdle and G. J. van den Berg, J. Nutr., 1992, 122, 1260–5. 
139 M. C. Linder, C. A. Goode, K. C. Weiss, P.-L. Wirth and M. H. Vu, in 
Metabolism of Minerals and Trace Elements in Human Disease, eds. M. 
Abdulla, H. Dashti, B. Sarkar, H. Al-Sayer and N. Al-Naqeeb, Smith-Gordon, 
London, 1989. 
140 G. Crisponi, V. M. Nurchi, D. Fanni, C. Gerosa, S. Nemolato and G. Faa, 
Coord. Chem. Rev., 2010, 254, 876–889. 
 

































































Muscle tissue may play an important role in the aetiology of amyotrophic lateral 
sclerosis, where accumulation in the tissue may aid in the development of the disease. 
































































Figure 1: Copper (A-C), Zn (D-F) and Fe (G-I) concentrations in spinal cord, brain and muscle tissue (µg g-1 
of dry tissue) as a function of time (days). Elevated concentrations of Cu, Zn and Fe are evident in muscle 
tissue and appear to precede the development of symptoms in Cu, while Zn and Fe are trailing the 
development of symptoms. Box plots show median values (solid horizontal line, 50th percentile (box outline), 
90th percentile (whiskers) and outlier values (filled circles); n ≥ 5.  
 
 
































































Figure 2: Copper (A), Zn (B) and Fe (C) concentrations in whole blood (µg g-1 of dry tissue) as a function of 
time (days). Box plots show median values (solid horizontal line, 50th percentile (box outline), 90th percentile 
(whiskers) and outlier values (filled circles); n ≥ 6.  
 
 
































































Figure 3: Copper isotope ratios in spinal cord (A), brain (B) and muscle tissue (C), as a function of time (in 
days). The gray line indicates the Cu isotope ratio of food (0.84 ± 0.03‰; ±2SE).  Box plots show median 
values (solid horizontal line, 50th percentile (box outline), 90th percentile (whiskers) and outlier values (filled 
circles); n ≥ 6.  
 
 
































































Figure 4: Copper isotope ratios in whole blood and feces against time (d), including food (gray line; 0.84 ± 
0.03‰; ±2SE). Box plots (A) show median values (solid horizontal line, 50th percentile (box outline), 90th 
percentile (whiskers) and outlier values (filled circles) (n ≥ 7). Results in plot B show mean ± 2SE (n = 6).  
 
 
































































Figure 5: Uptake of Cu into the fetus via the placenta. Ceruloplasmin, and other low molecular copper-
compounds, predominantly [Cu2+(His)2], accumulate the heavy isotope 
65Cu. This Cu then accumulates in 
the liver of the fetus after crossing the fetal endothelium, enriching it in 65Cu.  
 
 
































































Figure 6: Conceptual model for the presence of a ‘starting pool’ of heavy Cu received from the mother and 
accumulated in the fetal liver (A). This Cu is an initial source for the fast neonatal growth phase, distributing 
65Cu throughout the tissues. The commencement of ingestion of external non-maternal food (lighter Cu 
isotopic composition) meets the high nutrient requirement of juvenile growth (B). This dilutes the pre-
existing heavy Cu pool. The dilution continues until adult-hood, at which point growth stops and Cu isotope 
ratios stabilize, reflecting the food’s isotope ratio (C). At this point, localized recycling processes with 
endogenic and exogenic Cu are possible.  
 
 































































Results of the linear model with the following parameters: 
Dependent variables: Cu, Zn, Fe, CuIso (Cu isotope ratios) 
Independent variables: time (30, 60, 90, 120) and state (SOD1 and WT) 
 Time was treated as a continuous variable. 








Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 16.88036 2.62173 6.439 6.96e-08 *** 
stateWT -0.10929 2.00551 -0.054 0.95678  
time 0.08835 0.02940 3.005 0.00434 ** 
 
 
Cu Spinal cord 
Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 12.82288 2.35142 5.453 2.01e-06 *** 
stateWT -1.89467 1.79873 -1.053 0.298  




Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 12.75008 2.15083 5.928 4.31e-07 *** 
stateWT -10.00600 1.64097 -6.098 2.43e-07 *** 




Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 4.202613 0.512487 8.200 3.62e-11 *** 
stateWT -0.674357 0.375417 -1.796 0.0778 . 
time -0.003440 0.005556 -0.619 0.5383  
 
  































































Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 98.20885 11.56640 8.491 6.73e-11 *** 
stateWT -7.97077 8.84776 -0.901 0.372  
time 0.02585 0.12972 0.199 0.843  
 
 
Zn Spinal cord 
Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 60.0657 10.9858 5.468 2.03e-06 *** 
stateWT -13.4311 8.3714 -1.604 0.1158  




Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 72.8489 10.7452 6.780 2.68e-08 *** 
stateWT -39.3087 8.2716 -4.752 2.27e-05 *** 




Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 26.34043 3.48919 7.549 3.5e-10 *** 
stateWT -2.50953 2.62022 -0.958 0.342  



































































Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 107.82885 21.05521 5.121 1.52e-05 *** 
stateWT 5.84396 13.38300 0.437 0.665  
time 0.01305 0.23155 0.056 0.955  
 
 
Fe Spinal cord 
Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 79.4316 15.0040 5.294 3.63e-06 *** 
stateWT -1.9171 11.4334 -0.168 0.868  




Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 62.3861 12.2794 5.081 7.77e-06 *** 
stateWT -35.3730 9.4527 -3.742 0.000536 *** 




Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 1478.196 360.696 4.098 0.000129 *** 
stateWT 152.990 269.184 0.568 0.571956  
time 7.907 3.954 2.000 0.050130 . 
 
  































































Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 1.939807 0.198597 9.768 8.55e-13 *** 
stateWT -0.078462 0.150649 -0.521 0.6047  
time -0.005942 0.002227 -2.669 0.0105 * 
 
 
CuIso Spinal cord 
Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 1.81947 0.18462 9.855 6.46e-13 *** 
stateWT 0.01631 0.13995 0.117 0.908  




Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 2.327292 0.303983 7.656 1.10e-09 *** 
stateWT 0.287917 0.229790 1.253 0.217  




Coefficients:      
 Estimate Std. Error t value Pr(>|t|)  
(Intercept) 0.8819047 0.2003504 4.402 4.4e-05 *** 
stateWT -0.0017195 0.1488245 -0.012 0.991  
time 0.0008823 0.0022175 0.398 0.692  
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